Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn 60, Issue 3, 2005, Pages 257-264

  Chan, Vivien ^a   Charles, Bruce G ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

A77 1726; Concentration response; Leflunomide; NONMEM; Population pharmacokinetics; Rheumatoid arthritis

Indexed keywords

DRUG METABOLITE; LEFLUNOMIDE; TERIFLUNOMIDE;

ADULT; AGED; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CREATININE CLEARANCE; DISEASE ACTIVITY; DOSE RESPONSE; FEMALE; HUMAN; MALE; MEASUREMENT; MORNING STIFFNESS; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 36; STEADY STATE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANILINE COMPOUNDS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; MALE; MIDDLE AGED;

EID: 24044446145     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02415.x     Document Type: Review

References (25)

1. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002; 41: 421-30.
2. Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Invest Drugs 2001; 2: 222-30.
3. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl 1998; 25(Suppl 53): 20-6.
4. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, Popovic M, Dimitrijevic M, Ziukouic M, Campion G. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-603.
5. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Lowe-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigation Group. Arch Intern Med 1999; 159: 2542-50.
6. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66.
7. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, Van Den Bosch F, Nordstrom D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez De La Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew-Friedrich I. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
8. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis Trial Investigation Group. Arthritis Rheum 2001; 44: 1984-92.
9. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913-23.
10. Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, Clardy C, Foster P, Williams JA. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999; 68: 100-9.
11. Weber W, Harnisch L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis [Abstract]. Arthritis Rheum 1997; 40(Suppl 9): s153.
12. Infante R, Lahita RG. Rheumatoid arthritis. New disease-modifying and antiinflammatory drugs. Geriatrics 2000; 55: 30-2,35-6,39-40.
13. Li J, Yao HW, Jin Y, Zhang YF, Li CY, Li YH, Xu SY. Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 2002; 23: 551-5.
14. Shi J, Kovacs SJ, Ludden TM, Bhargava V. Population pharmacokinetics (PPK) analysis of A77 1726 (M1) after oral administration of leflunomide (LEF) in pediatric subjects with polyarticular course juvenile rheumatoid arthritis (HRA) [Abstract]. Clin Pharmacol Ther 2004; 75: P5.
15. Weber W, Harnisch L. Leflunomide in rheumatoid arthritis: Population pharmacokinetic analysis of phase III studies [Abstract]. 11th European League Against Rheumatism (EULAR) Symposium 1998, September 5-8: Geneva, Switzerland, 158.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Chan V, Charles BG, Tett SE. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography. J Chromatogr B 2004; 803: 331-5.
18. NONMEM Project Group. NONMEM Users Guide, eds. Beal SL, Sheiner LB. San Francisco, University of California, 1992.
19. Linton SJ, Gotestam KG. A clinical comparison of two pain scales: correlation, remembering chronic pain, and a measure of compliance. Pain 1983; 17: 57-65.
20. Duncan GH, Bushnell MC, Lavigne GJ. Comparison of verbal and visual analogue scales for measuring the intensity and unpleasantness of experimental pain. Pain 1989; 37: 295-303.
21. Clark P, Lavielle P, Martinez H. Learning from pain scales: patient perspective. J Rheumatol 2003; 30: 1584-8.
22. Paterson C. Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey. Br Med J 1996; 312: 1016-20.
23. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Pharmaceutical Society of Australia Royal Australian College of General Practitioners. Australian Medicines Handbook 2004, 5th edn. Adelaide: Australian Medicines Handbook Pty Ltd, 2004.
24. Fiehn C, Rochel E, Ho AD, Max R. Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF [Letter]. Ann Rheum Dis 2004; 63: 746-7.
25. Kamali S, Kasapoglu E, Uysal M, Inanc M, Gul A. An unusual overdose of leflunomide in a patient with rheumatoid arthritis [Letter]. Ann Pharmacother 2004; 38: 1320-1.